Investment Thesis

.

Competitive Moat

Eli Lilly benefits from a strong intangible asset moat, bolstered by a deep portfolio of proprietary drugs and an extensive pipeline that includes first-in-class treatments. Its established brand recognition and ongoing investments in R&D create high switching costs for healthcare providers and patients. This competitive advantage is durable over the next 5-10 years, particularly as LLY continues to innovate in high-growth areas such as diabetes care and oncology. Key competitive threats include emerging biosimilars and the rapid advancement of alternative therapies from rivals like Novo Nordisk and Merck.

Growth Engine

Future revenue growth for Eli Lilly is expected to be primarily driven by its leading diabetes products, including Trulicity and a new oral GLP-1 offering, which collectively address a substantial total addressable market (TAM) projected to exceed $40 billion. Additionally, the oncology division, particularly therapies targeting breast and lung cancers, is positioned for significant expansion as patient demographics shift towards an aging population. Market share is being gained through strategic pricing power and a focus on innovative drug delivery systems, positioning LLY favorably against its competitors.